Items Tagged ‘bortezomib’

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

By

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]

View full entry

Tags: ASCT, bortezomib, clinical trial, cyclophosphamide, dexamethasone, HOVON, Multiple Myeloma, News, Stem Cell Transplant, velcade


December 21st, 2015

Addition of Velcade® to Revlimid®/Dexamethasone Improves Survival in Newly Diagnosed Multiple Myeloma

By

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately undergo a stem cell transplant. These results were presented at the 2015 annual meeting of the American Society of Hematology in […]

View full entry

Tags: bortezomib, Multiple Myeloma, News, revlimid, velcade


February 25th, 2015

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma

By

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including Velcade® and an immunomodulatory (IMiD) agent. The FDA approval was partially based on the results of the […]

View full entry

Tags: bortezomib, farydak, Multiple Myeloma, News, panobinostat, Recurrent Multiple Myeloma, velcade